Dr. Shu’s research primarily focus on identifying novel genetic and molecular markers for cancer risk, with the goal of better understanding cancer etiology and developing novel tools for risk assessment. He actively participates in multiple international consortia including the Breast Cancer Association Consortium, the Genetics and Epidemiology of Colorectal Cancer Consortium, the Asia Breast Cancer Consortium, and the Asia Colorectal Cancer Consortium, etc. Dr. Shu are leading multiple projects integrating genetic information with omics data in these consortia. Dr. Shu is also an investigator in three large prospective cohorts, the Shanghai Women’s Health Study, the Shanghai Men’s Health Study, and the Southern Community Cohort Study. He has been leading/involved in multiple research projects in these cohorts to search for novel risk biomarkers for colorectal, pancreatic, gastric, gallbladder, and ovarian cancer using metabolomics and proteomics. By examining the potential mediating effects of metabolites and proteins, new knowledge will be gained on how modifiable factors such as diet and exercise affect cancer risk.